Form D · Other
Progentos Therapeutics, Inc.
Watertown, MA · CIK 0002014427
Offering snapshot reported May 17, 2024 · SEC filing
- Reported sold
- $68.6M Offering amount: $68.6M
- Investors reported
- 39 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 3, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 17, 2024 | Initial | $68,588,739 | No comparison | 39 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-513638
Includes conversion of convertible notes
Source: Form D, filed May 17, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Cassidy Blundell | Director |
| Dmitrij Hristodorov | Director |
| Dan Janney | Director |
| Christopher Loose | Director, Executive |
| Sanjay Magavi | Executive |
| Aleks Radovic Moreno | Director |
| Marc Olivier Turgeon | Director |
Issuer details
Industry: Other (See others in industry)
Address:
200 Dexter Avenue
Watertown, MA, 02472
Watertown, MA, 02472